Cargando…

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin

Concurrent administration of two drugs may complicate the management of acute coronary syndromes: competitive drug displacement diminishes drug binding and alters drug pharmacodynamics. We investigated the interaction of two antiplatelet compounds (PSB 0777 and cangrelor) with human serum albumin (H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wzorek, Joanna, Bednarek, Radosław, Watala, Cezary, Boncler, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990796/ https://www.ncbi.nlm.nih.gov/pubmed/33776774 http://dx.doi.org/10.3389/fphar.2021.638257

Ejemplares similares

Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y(12) Receptor Antagonists
por: Wolska, Nina, et al.
Publicado: (2019)

The cardioprotective power of leaves
por: Dudzińska, Dominika, et al.
Publicado: (2015)

The Multiple Faces of C-Reactive Protein—Physiological and Pathophysiological Implications in Cardiovascular Disease
por: Boncler, Magdalena, et al.
Publicado: (2019)

Interactions of fentanyl with blood platelets and plasma proteins: platelet sensitivity to prasugrel metabolite is not affected by fentanyl under in vitro conditions
por: Bednarek, Radosław, et al.
Publicado: (2023)

A new approach for the assessment of the toxicity of polyphenol-rich compounds with the use of high content screening analysis
por: Boncler, Magdalena, et al.
Publicado: (2017)

CD39/NTPDase-1 expression and activity in human umbilical vein endothelial cells are differentially regulated by leaf extracts from Rubus caesius and Rubus idaeus
por: Dudzinska, Dominika, et al.
Publicado: (2014)

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus
por: Polak, Dawid, et al.
Publicado: (2021)

Diabetes and Hyperglycemia Affect Platelet GPIIIa Expression: Effects on Adhesion Potential of Blood Platelets from Diabetic Patients under In Vitro Flow Conditions
por: Przygodzki, Tomasz, et al.
Publicado: (2020)

Fibrinogen Glycation and Presence of Glucose Impair Fibrin Polymerization—An In Vitro Study of Isolated Fibrinogen and Plasma from Patients with Diabetes Mellitus
por: Luzak, Boguslawa, et al.
Publicado: (2020)

SARS-CoV-2 Spike Protein and Neutralizing Anti-Spike Protein Antibodies Modulate Blood Platelet Function
por: Luzak, Boguslawa, et al.
Publicado: (2023)

Extract from Ribes nigrum leaves in vitro activates nitric oxide synthase (eNOS) and increases CD39 expression in human endothelial cells
por: Luzak, Boguslawa, et al.
Publicado: (2014)

Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience
por: Rossini, Roberta, et al.
Publicado: (2020)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Efficacy of Cangrelor as Bridging Therapy Post PCI
por: Khan, Abdul A., et al.
Publicado: (2020)

The Sulfolobus solfataricus radA paralogue sso0777 is DNA damage inducible and positively regulated by the Sta1 protein
por: Abella, Marc, et al.
Publicado: (2007)

Purification and Identification of Activating Enzymes of CS-0777, a Selective Sphingosine 1-Phosphate Receptor 1 Modulator, in Erythrocytes
por: Yonesu, Kiyoaki, et al.
Publicado: (2011)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein
por: Bednarek, Radosław, et al.
Publicado: (2023)

The Mystery behind the Pineal Gland: Melatonin Affects the Metabolism of Cholesterol
por: Karolczak, Kamil, et al.
Publicado: (2019)

Safety and Efficacy of Cangrelor Among Three Antiplatelet Regimens During Stent-Assisted Endovascular Treatment of Unruptured Intracranial Aneurysm: A Single-Center Retrospective Study
por: Cheddad El Aouni, Mourad, et al.
Publicado: (2022)

Cangrelor Use in Routine Practice: A Two-Center Experience
por: van der Sangen, Niels M. R., et al.
Publicado: (2021)

Antiplatelet Agents Inhibit the Generation of Platelet-Derived Microparticles
por: Giacomazzi, Alice, et al.
Publicado: (2016)

Cangrelor bridging strategy for liver damage after mechanical chest compression
por: Cereda, Alberto Francesco, et al.
Publicado: (2019)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

The Janus Face of PAMAM Dendrimers Used to Potentially Cure Nonenzymatic Modifications of Biomacromolecules in Metabolic Disorders—A Critical Review of the Pros and Cons
por: Labieniec-Watala, Magdalena, et al.
Publicado: (2013)

Antiplatelet and Antithrombotic Activity of a Traditional Medicine, Hwangryunhaedok-Tang
por: Kim, Kyungho, et al.
Publicado: (2019)

Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
por: Jourdi, Georges, et al.
Publicado: (2022)

Elucidation of the binding mechanism of astragaloside IV derivative with human serum albumin and its cardiotoxicity in zebrafish embryos
por: Wu, You-Jiao, et al.
Publicado: (2022)

Plant Alkaloids as Antiplatelet Agent: Drugs of the Future in the Light of Recent Developments
por: Ain, Qurrat-Ul-, et al.
Publicado: (2016)

Platelet-Derived Extracellular Vesicles as Target of Antiplatelet Agents. What Is the Evidence?
por: Taus, Francesco, et al.
Publicado: (2019)

Pharmacokinetics, Tissue Distribution, and Human Serum Albumin Binding Properties of Delicaflavone, a Novel Anti-Tumor Candidate
por: Chen, Bing, et al.
Publicado: (2021)

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17
por: Luo, Qiancheng, et al.
Publicado: (2021)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease
por: Wawruch, Martin, et al.
Publicado: (2021)

Sample Preparation as a Critical Aspect of Blood Platelet Mitochondrial Respiration Measurements—The Impact of Platelet Activation on Mitochondrial Respiration
por: Siewiera, Karolina, et al.
Publicado: (2021)

Phospholipase Cγ2 Signaling Cascade Contribute to the Antiplatelet Effect of Notoginsenoside Fc
por: Liu, Yingqiu, et al.
Publicado: (2018)

Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria
por: Hannachi, Nadji, et al.
Publicado: (2020)

Serum Albumin–Peptide Conjugates for Simultaneous Heparin Binding and Detection
por: Liu, Qing, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7njpbfsmmh7kchrm9q45bm38o6